肺癌相关驱动基因及靶向治疗的研究进展

Research Progress of Driver Oncogene and Target Therapy in Lung Cancer

近年来肺癌分子生物学发展迅速,尤其在肺癌相关驱动基因及靶向治疗方面取得了显著进展。事实上,肺癌中的这些驱动基因已经被人类探索很长时间,只是相应靶向治疗药物仍在探索中,第二代测序技术的推广应用进一步推动了肺癌的驱动基因研究,为靶向治疗提供了潜在分子靶点。最近,在肺癌领域又出现了新的驱动基因,这些驱动基因的靶向药物也将有望会被陆续研发,并将会为肺癌的精准治疗助力,但是大部分患者经靶向治疗后会产生耐药,疗效仍不能满意。因此,基于肺癌基因驱动的机制探索及多靶点联合治疗是未来研究的方向。

Many advances have been achieved in recent years in the field of lung cancer molecular biology,leading to the identification of potential new oncogene drivers and new therapeutic targets. Most of lung cancer biomarkers were identi- fied several years ago, nevertheless, new therapies targeting these biomarkers are still investigated. The next generation sequencing is widely used ,which further promotes the studies of lung cancer driver genes and provides potential molecular targets for effective targeted therapies. More recently, new oncogene drivers have been identified in the field of lung carcino- ma and new agents are being developed to target these biomarkers, which will help with the precise treatment of lung cancer. However, most patients can develop resistance after targeted therapy, and the efficacy is not satisfactory. Therefore, the mechanism exploration and multi-target combination therapy based on driver gene of lung cancer is the future research direction.